- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01744314
Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma
March 22, 2017 updated by: George Athwal, Lawson Health Research Institute
Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma: A Randomized Prospective Double-blinded Study.
Patients who present to our institution with a traumatic injury to their elbow who need operative management will be randomized to one of two groups; a treatment arm and a control arm.
The treatment arm will receive a three-week postoperative course of indomethacin while the control group will not.
We will follow both groups to assess whether or not indomethacin prophylaxis affects the rate of heterotopic ossification.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: George Athwal, MD
- Phone Number: 66081 519-646-6100
- Email: <gathwal@uwo.ca>
Study Contact Backup
- Name: Kate Kelly, MSc, MPH
- Phone Number: 64640 519-646-6100
- Email: Kate.Kelly@sjhc.london.on.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4V2
- Recruiting
- HULC, St Joseph's Health Care
-
Contact:
- George Athwal, MD
- Phone Number: 519-646-6100
- Email: gathwal@uwo.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Terrible Triad
- Radial head fracture surgical treatment
- Monteggia and Trans-olecranon Fracture Dislocations
- Distal Biceps Tendon Injuries
- Distal Humerus Fractures
- Coronoid Fractures
- Capitellar-Trochlear fractures
- Olecranon Fractures
Exclusion Criteria:
- Associated Traumatic Brain Injury
- Burn Injuries associated with elbow trauma
- History of Gastric Ulcers
- Documented allergies to any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Severe Asthma
- Previous operative fixation to affected elbow
- Participation in other research study
- Inability to speak / understand English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: drug
The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent).
The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
|
|
Placebo Comparator: placebo
The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control.
The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in post operative radiographic evaluation
Time Frame: 6 weeks and 3, 6 and 12 mfup
|
AS a standard care patients will be routinely assess at three, six , twelve and twenty four months post-operatively.
|
6 weeks and 3, 6 and 12 mfup
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in range of motion
Time Frame: 6 weeks and 3, 6 and 12 mfup
|
measuring range of motion with a goniometer will be performed at 6 weeks and 3, 6 and 12 mfup
|
6 weeks and 3, 6 and 12 mfup
|
Patient Rate Elbow Evaluation
Time Frame: 6 weeks and 3, 6 and 12 mfup
|
is a 20-item questionnaire designed to measure elbow pain and disability
|
6 weeks and 3, 6 and 12 mfup
|
The Mayo Elbow Performance score
Time Frame: 6 weeks and 3, 6 and 12 mfup
|
is an instrument used to test the limitations to use the elbow during ADL caused by the pathology
|
6 weeks and 3, 6 and 12 mfup
|
Disabilities of the Arm, Shoulder and Hand
Time Frame: 6 weeks and 3, 6 and 12 mfup
|
is a 30-item, self-report questionnaire designed to measure physical function and symptoms in people with any of several musculoskeletal disorders of the upper limb.
|
6 weeks and 3, 6 and 12 mfup
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Anticipated)
November 1, 2019
Study Completion (Anticipated)
November 1, 2019
Study Registration Dates
First Submitted
November 19, 2012
First Submitted That Met QC Criteria
December 5, 2012
First Posted (Estimate)
December 6, 2012
Study Record Updates
Last Update Posted (Actual)
March 23, 2017
Last Update Submitted That Met QC Criteria
March 22, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Wounds and Injuries
- Ossification, Heterotopic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gastrointestinal Agents
- Reproductive Control Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Gout Suppressants
- Tocolytic Agents
- Indomethacin
- Pantoprazole
Other Study ID Numbers
- 102903
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Elbow Trauma Requiring Operative Management
-
Catholic University of the Sacred HeartCompleted
-
National Hepatology & Tropical Medicine Research...Completed
-
St George's Healthcare NHS TrustUnknownPeri-operative Fluid Management
-
American University of Beirut Medical CenterCompletedPost-Operative Complications | Intra-Operative Ventilatory ManagementLebanon
-
Nantes University HospitalCompletedSymptomatic Haemorrhoidal Disease Requiring Surgical ManagementFrance
-
EarlySense Ltd.WithdrawnPost Operative Patient | Patients Requiring PCA | Respiratory Patients | Patients in Risk of FallUnited States
-
St. Luke's Hospital, PennsylvaniaUnknownCesarean Section Post Operative ManagementUnited States
-
Lisa J. FrymanTerminatedTrauma Patients Requiring Physical RehabilitationUnited States
-
Wayne State UniversityNot yet recruiting
-
Wayne State UniversityRecruitingPost-operative Pain ManagementUnited States
Clinical Trials on Indomethacin and Pantoprazole
-
AbbottCompleted
-
Kwong Wah HospitalCompleted
-
Alexandria UniversityCompletedPortal Hypertension | Variceal Hemorrhage | Ulcer HemorrhageEgypt
-
PfizerRecruitingEsophagitisBelgium, United States, United Kingdom, Serbia, Georgia, Hungary, Bosnia and Herzegovina, Puerto Rico, Turkey, Slovakia, India
-
National Taiwan University HospitalUnknownBleeding | Peptic Ulcer | Endoscopy | Proton Pump InhibitorsTaiwan
-
TakedaWithdrawnGastric pH ControlMexico
-
University of Auckland, New ZealandCompletedBreast Cancer | Chemotherapy-induced Nausea and Vomiting | OncologyNew Zealand
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedGastroesophageal Reflux
-
PfizerTerminatedGastroesophageal Reflux DiseaseUnited States, Bosnia and Herzegovina, Slovakia, Italy, Germany, Argentina, Georgia, Serbia, Ukraine
-
Emory UniversityWyeth is now a wholly owned subsidiary of PfizerCompleted